![]() |
市場調查報告書
商品編碼
1660672
2025 年至 2033 年心室輔助裝置市場報告(按產品、流量類型、產品類型、應用、最終用戶和地區)Ventricular Assist Devices Market Report by Product, Flow Type, Product Type, Application, End User, and Region 2025-2033 |
2024IMARC Group全球心室輔助裝置市場規模達到 21 億美元。心臟衰竭盛行率不斷上升、捐贈心臟數量有限、支持性監管框架和更快的核准速度、心臟輔助裝置植入手術技術的改進以及技術進步是推動市場發展的一些關鍵因素。
心室輔助裝置 (VAD) 是一種用於支持衰弱或衰竭心臟功能的醫療設備。它們主要用作患者等待心臟移植期間的臨時措施或作為不符合移植條件的患者的長期解決方案。心室輔助裝置 (VAD) 是透過手術植入的,有助於將血液從心室泵送到身體的其他部位。這些設備由一個通常放置在患者腹部或胸部的幫浦和一條將幫浦連接到外部電源的傳動系統組成。此幫浦負責接管心臟的泵血功能,確保血液充分循環至全身。它們可以幫助緩解症狀,包括疲勞、呼吸急促和體液滯留。此外,心臟輔助裝置可以作為移植的橋樑,使患者保持穩定,並提高他們接受捐贈心臟的機會。因此,VAD 徹底改變了心臟衰竭的治療方法,並提高了患者的生活品質、能量水平和存活率。
心血管疾病(CVD)盛行率的上升是推動市場成長的關鍵因素之一。除此之外,醫療專業人員和患者對 VAD 治療的好處和可用性的認知不斷提高,這也促進了市場的擴張。向醫療服務提供者、患者和護理人員宣傳 VAD 在治療心臟衰竭方面的有效性的力度不斷加大,使得這些設備的接受度和採用率不斷提高。此外,支持性監管框架和批准促進了 VAD 的商業化和採用。世界各地的監管機構一直積極參與簡化核准流程、確保安全並促進 VAD 技術的創新。這種有利的監管環境鼓勵製造商投資研發並推出先進的 VAD。此外,VAD植入手術技術的進步使得手術更加安全、更容易。開胸手術或肋下切口等微創(MI)手術方法的引入,減少了手術創傷,縮短了恢復時間,擴大了患者接受 VAD 治療的資格,從而加速了 VAD 的採用。此外,醫療保健支出的增加(特別是在新興經濟體)也促進了 VAD 市場的成長。其他因素,包括顯著的經濟成長、不斷改善的醫療保健基礎設施、政府為提高醫療保健服務而採取的有利舉措以及患者對投資心臟衰竭新治療方案的意願不斷增強,預計也將刺激市場成長。
心臟衰竭盛行率增加
全球範圍內心衰竭盛行率的不斷上升是推動心室輔助裝置市場發展的重要因素。心臟衰竭病例的增加可歸因於人口老化、個人久坐的生活方式、肥胖以及糖尿病和高血壓等慢性疾病的增加。心臟衰竭的風險隨著年齡的成長而增加,老年人更有可能需要機械循環支持。人口老化,尤其是已開發國家的人口老化,為 VAD 創造了大量的患者群體,從而推動了市場成長。隨著心臟衰竭患者數量的不斷成長,對 VAD 作為可行治療選擇的需求也在增加。 VAD 為患有晚期心臟衰竭、可能無法對常規療法做出充分反應的患者提供了解決方案,提供了機械支持並改善了他們的生活品質。
捐獻心臟數量有限
適合移植的捐贈心臟的稀缺性是推動市場成長的另一個關鍵因素。心臟移植仍然是末期心臟衰竭的黃金標準治療方法。然而,可供捐贈的心臟數量遠遠無法滿足需求。由於心臟輔助裝置 (VAD) 可充當移植的橋樑,保持患者病情穩定,並提高他們接受捐贈心臟的機會,因此它們擴大被用作不適合移植的患者的長期解決方案。因此,合適心臟捐贈者的有限性產生了對心臟移植替代方案的需求,例如 VAD,預計這將在預測期內進一步推動市場的成長。
科技進步的崛起
VAD 技術的快速進步極大地促進了市場的成長。主要參與者的持續研究和開發 (R&D) 努力使得設備尺寸更小、耐用性更高、控制系統增強、患者治療效果更好。這些技術進步將 VAD 的使用範圍擴大到了更廣泛的患者群體,包括體型較小的患者或患有心臟衰竭的兒童。此外,設備設計和植入技術的進步降低了併發症的風險,提高了設備的可靠性,並改善了患者的舒適度。 VAD 技術的創新和改進促進了更有效率、更安全、對醫療專業人員和患者都更具吸引力的創新設備的開發,從而支持了市場成長。
The global ventricular assist devices market size reached USD 2.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.3 Billion by 2033, exhibiting a growth rate (CAGR) of 8.06% during 2025-2033. The growing prevalence of heart failure, limited availability of donor hearts, supportive regulatory framework and faster approvals, improvements in surgical techniques for VAD implantation, and technological advancements represent some of the key factors propelling the market.
Ventricular assist devices (VADs) are medical devices designed to support the functioning of a weakened or failing heart. They are primarily used as a temporary measure while a patient awaits a heart transplant or as a long-term solution for patients who are not eligible for transplantation. VADs are implanted surgically and help pump blood from the heart's ventricles to the rest of the body. These devices consist of a pump, which is typically placed in the patient's abdomen or chest, and a driveline that connects the pump to an external power source. The pump is responsible for taking over the pumping action of the heart, ensuring that blood is adequately circulated throughout the body. They can help relieve symptoms, including fatigue, shortness of breath, and fluid retention. Moreover, VADs can serve as a bridge to transplantation, keeping patients stable and improving their chances of receiving a donor heart. As a result, VADs have revolutionized the treatment of heart failure, providing patients with improved quality of life, higher energy levels, and increased survival rates.
A rise in the prevalence of cardiovascular diseases (CVDs) represents one of the key factors driving market growth. Besides this, the growing awareness among healthcare professionals and patients about the benefits and availability of VAD therapy is contributing to the market expansion. A surge in efforts to educate healthcare providers, patients, and caregivers about the effectiveness of VADs in managing heart failure has led to increased acceptance and adoption of these devices. In addition, supportive regulatory frameworks and approvals have facilitated the commercialization and adoption of VADs. Regulatory agencies worldwide have been actively involved in streamlining the approval process, ensuring safety, and promoting innovation in VAD technology. Such favorable regulatory environments encourage manufacturers to invest in research and development (R&D) and introduce advanced VADs. Additionally, advancements in surgical techniques for VAD implantation have made the procedure safer and more accessible. The introduction of minimally invasive (MI) surgical approaches, such as thoracotomy or subcostal incisions, has reduced surgical trauma, shortened recovery times, and expanded the eligibility of patients for VAD therapy, which in turn has accelerated the adoption of VADs. Furthermore, the increasing healthcare expenditure, particularly in emerging economies, is contributing to the growth of the VADs market. Other factors, including significant economic growth, improving healthcare infrastructure, favorable government initiatives to enhance healthcare access, and the rising willingness of patients to invest in novel treatment options for heart failure, are also anticipated to stimulate market growth.
Increase in the prevalence of heart failure
The growing prevalence of heart failure across the globe is a significant factor driving the market for ventricular assist devices. The rise in heart failure cases can be attributed to the aging population, sedentary lifestyles of individuals, obesity, and an increase in chronic diseases such as diabetes and hypertension. The risk of heart failure rises with age, and older adults are more likely to require mechanical circulatory support. The aging population, especially in developed countries, creates a substantial patient pool for VADs, fueling market growth. As the number of heart failure patients continues to grow, the demand for VADs as a viable treatment option also increases. VADs offer a solution for individuals with advanced heart failure who may not respond adequately to conventional therapies, providing mechanical support and improving their quality of life.
Limited availability of donor hearts
The scarcity of suitable donor hearts for transplantation is another critical factor strengthening the market growth. Heart transplantation remains the gold standard treatment for end-stage heart failure. However, the number of available donor hearts falls significantly short of the demand. Since VADs serve as a bridge to transplantation, keeping patients stable and improving their chances of receiving a donor heart, they are increasingly being used as a long-term solution for patients who are not eligible for transplantation. As a result, the limited availability of suitable heart donors has generated the need for alternatives to heart transplantation, such as VADs, which is further expected to fuel the growth of the market during the forecast period.
Rise in technological advancements
Rapid advancements in VAD technology have significantly contributed to the growth of the market. Continuous research and development (R&D) efforts by key players have led to smaller device sizes, improved durability, enhanced control systems, and better patient outcomes. These technological advancements have expanded the use of VADs to a broader patient population, including those with smaller body sizes or children with heart failure. Moreover, advancements in device design and implantation techniques have reduced the risk of complications, increased device reliability, and improved patient comfort. Such innovations and improvements in VAD technology have led to the development of innovative devices that are more efficient, safer, and appealing to both healthcare professionals and patients, thereby supporting market growth.
Left ventricular assist device (LVAD) represents the most popular product
Non-pulsatile or continuous flow dominates the market
Implantable ventricular assist devices represent the largest product type
Bridge-to-transplant (BTT) therapy accounts for the majority of the market share
Hospital holds the leading position in the market
North America exhibits a clear dominance in the market
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for ventricular assist devices.